DUTSCHER acquired by LBO FRANCE
Context
LBO France acquired a controlling stake in Dutscher, replacing Five Arrows (who had held the majority since 2014). This Secondary LBO also marked the exit of the founder's son, who held ~40% but had no operational role, completing the transition from a family-owned business to a financial-backed platform.
It is worth noting that the fund Five Arrows took control of Dutscher through an LBO in 2014.
DUTSCHER, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of 5x–12x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Headquartered in Alsace, Dutscher is a leading European distributor of consumables (pipettes, reagents) and equipment for research and medical laboratories. The company acts as a "one-stop-shop" for public research institutes and biotech companies. Under LBO France's ownership (2020-2026), Dutscher transformed from a French-centric player into a pan-European platform. It completed 13 add-on acquisitions ("build-ups"), expanding its footprint into the Nordics (Denmark, Sweden, Finland), the Baltics, and strengthening its presence in the UK/Ireland.
Ent. Value
€100–350M
Equity Value
[members only]
Multiples
EV / Revenue
below 1.5x
EV / EBITDA
5x–12x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with DUTSCHER
Other operations with DUTSCHER
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 04/2020 | WARBURG PINCUS | POLYPLUS | FRANCE | R&D Biotech |
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
| 02/2020 | TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 10/2019 | DENTRESSANGLE | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 09/2019 | SAGARD | STERIMED | FRANCE | Medical Consumables |
| 08/2019 | PERMIRA | CAMBREX CORPORATION | UNITED STATES | CDMO |
| 07/2019 | PERMIRA | QUOTIENT SCIENCES | UNITED KINGDOM | CDMO |
| 07/2019 | BC PARTNERS | Synthon International | NETHERLANDS | Generics / Labs |
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
Other operations with LBO FRANCE
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2025 | LBO FRANCE | HEMODIA | FRANCE | Medical Devices |
| 12/2021 | LBO FRANCE | ALLIANCE MARINE | FRANCE | Sport |
| 11/2020 | LBO FRANCE / ANDERA PARTNERS | PRENAX GROUP | SWEDEN | BPO & Outsourcing |
| 03/2019 | LBO FRANCE | GROUPE PASSMAN | FRANCE | IT Equipment |
| 03/2019 | LBO FRANCE | INFODIS | FRANCE | Consulting & Integration |
| 12/2017 | LBO FRANCE | CROUZET | FRANCE | Sensors & Optics |
| 04/2015 | LBO FRANCE | IKKS GROUP | FRANCE | Fashion & Apparel |
| 10/2010 | LBO FRANCE | MATERNE-MONTBLANC (MOM GROUP) | FRANCE | Food Products |
| 06/2005 | LBO FRANCE | ACTARIS | FRANCE | Instrumentation & Measurement |
| 09/2003 | LBO FRANCE | MATERIS | LUXEMBOURG | Construction Materials |
REFERENCES
Valuation range: EV €100–350M
Revenue range: €150–250M
EBITDA range: €5–25M
EV/Revenue range: below 1.5x
EV/EBITDA range: 5x - 12x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DUTSCHER by LBO FRANCE are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: lbo france